Anteris Technologies Global Corp - Asset Resilience Ratio
Anteris Technologies Global Corp (AVR) has an Asset Resilience Ratio of 33.27% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Anteris Technologies Global Corp's Asset Resilience Ratio has changed over time. Check Anteris Technologies Global Corp PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Anteris Technologies Global Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Anteris Technologies Global Corp stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$43.38 Million | 33.27% |
| Total Liquid Assets | AU$43.38 Million | 33.27% |
Asset Resilience Insights
- Very High Liquidity: Anteris Technologies Global Corp maintains exceptional liquid asset reserves at 33.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Anteris Technologies Global Corp Industry Peers by Asset Resilience Ratio
Compare Anteris Technologies Global Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Edwards Lifesciences Corp
NYSE:EW |
Medical Devices | 9.20% |
|
DexCom Inc
NASDAQ:DXCM |
Medical Devices | 19.55% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212 |
Medical Devices | 6.09% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Corentec Co Ltd
KQ:104540 |
Medical Devices | 2.80% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Annual Asset Resilience Ratio for Anteris Technologies Global Corp (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Anteris Technologies Global Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 33.27% | AU$43.38 Million ≈ $30.69 Million |
AU$130.39 Million ≈ $92.26 Million |
+32.89pp |
| 2022-12-31 | 0.38% | AU$88.76K ≈ $62.80K |
AU$23.48 Million ≈ $16.61 Million |
+0.08pp |
| 2021-12-31 | 0.30% | AU$88.56K ≈ $62.66K |
AU$29.48 Million ≈ $20.86 Million |
-0.58pp |
| 2020-12-31 | 0.88% | AU$111.00K ≈ $78.54K |
AU$12.65 Million ≈ $8.95 Million |
-26.57pp |
| 2019-12-31 | 27.44% | AU$7.14 Million ≈ $5.05 Million |
AU$26.00 Million ≈ $18.40 Million |
+10.46pp |
| 2018-12-31 | 16.99% | AU$5.41 Million ≈ $3.83 Million |
AU$31.86 Million ≈ $22.54 Million |
-1.02pp |
| 2017-12-31 | 18.01% | AU$5.11 Million ≈ $3.61 Million |
AU$28.37 Million ≈ $20.07 Million |
-- |
| 2016-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$28.58 Million ≈ $20.22 Million |
-- |
| 2015-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$26.78 Million ≈ $18.95 Million |
-- |
| 2010-12-31 | 1.98% | AU$291.36K ≈ $206.16K |
AU$14.75 Million ≈ $10.44 Million |
-- |
About Anteris Technologies Global Corp
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calci… Read more